Salivary metabolomics for early detection of vascular contributions to cognitive impairment and dementia: Exploring microbiome dysbiosis and sex differences.

Authors

• Ali Yilmaz, Corewell Health East
• Nadia Ashrafi, Corewell Health East
• Zoe Guerra, Corewell Health East
• Nazia Saiyed, Corewell Health East
• Tammy Osentoski, Corewell Health East
• Suriah Khan, Corewell Health East
• Amita Pai, Corewell Health East
• Stacey Ruff, Corewell Health East
• Michael E. Maddens, Corewell Health East
• Khaled Imam, Corewell Health East
• Stewart F. Graham, Corewell Health East

Document Type

Article

Publication Date

4-2026

Publication Title

Journal of Alzheimer's disease : JAD

Abstract

BackgroundVascular factors contribute to dementia in approximately 20 million individuals, notably in vascular contributions to cognitive impairment and dementia (VCI). However, the lack of specific molecular biomarkers to differentiate VCI from normal aging and Alzheimer's disease (AD) impedes early diagnosis and treatment.ObjectiveTo date the use of saliva for VCI diagnosis has not been previously reported. In this small proof-of-concept study, we aim to explore the feasibility of screening novel salivary diagnostic biomarkers for VCI.MethodsUsing both proton nuclear magnetic resonance (

Volume

110

Issue

3

First Page

1235

Last Page

1247

Recommended Citation

Yilmaz A, Ashrafi N, Guerra Z, Goniwiecha D, Saiyed N, Gordevičius J et al [Osentoski T, Khan S, Pai A, Ruff S, Maddens ME, Imam K, Graham SF] Salivary metabolomics for early detection of vascular contributions to cognitive impairment and dementia: Exploring microbiome dysbiosis and sex differences. J Alzheimers Dis. 2026 Apr;110(3):1235-1247. doi: 10.1177/13872877261423158. PMID: 41837772.

DOI

10.1177/13872877261423158

ISSN

1875-8908

PubMed ID

41837772